Agile Therapeutics shares took a dip on Tuesday after the company announced a key FDA approval for its new weekly contraceptive patch. Yet, one analyst sees great long-term potential, targeting the stock to more…
These three biotech stocks have gigantic upside and a fair amount of risk as well. While they are not suited for conservative accounts, the companies all have had very positive data and their shares…
Revolution Medicines entered the market with a bang on Thursday. Although the company only priced shares are $17 apiece, the stock actually entered the market closer to $28.
The January 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
CVS Health has faced strong headwinds since last year’s acquisition of health insurer Aetna, but its upcoming earnings report could prove to be a turning point.
24/7 Wall St. screened the Merrill Lynch health care research database looking for large pharmaceutical leaders that also pay solid and dependable dividends. These five make sense for growth and income investors.
Moderna Inc. (NASDAQ: MRNA) had been the biggest biotech initial public offering ever. The company was quite unlucky in the timing for its IPO, but it managed to get back into favor with investors.…
The WHO is convening a meeting Tuesday in Geneva to give researchers and medical practitioners a chance to share information about the coronavirus outbreak. That will help battle the disease, but could more have…
Amarin is a development-stage biotechnology company with one FDA-approved treatment, a cardiovascular disease drug with no real competition. The company looks well-poised to boost sales in 2020 and going forward.
Collegium Pharma shares popped on Friday after the firm announced that it will acquire the U.S. rights to the Nucynta franchise from Assertio Therapeutics.
Aquestive Therapeutics shares jumped on Thursday after the firm announced that it had a constructive face-to-face meeting with the FDA concerning its “first of its kind” treatment of anaphylaxis.